MetaVia receives IRB approval for higher-dose obesity drug trial

March 18, 2026 8:01 AM

MetaVia Inc. (NASDAQ: MTVA) received Institutional Review Board approval to begin Phase 1 Part 3 clinical trials of DA-1726, its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found